FibroGen Announces Q3 Earnings Per Share of $3.25, Below Consensus Estimate of $4.01
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 10 2025
0mins
Should l Buy ?
Q3 Revenue Report: FibroGen reported Q3 revenue of $1.08 million, falling short of the consensus estimate of $1.64 million.
Operational Changes: The company completed the sale of its FibroGen China operations, simplifying its capital structure and extending its cash runway into 2028.
Clinical Trials Update: FibroGen initiated a Phase 2 monotherapy trial for FG-3246 and its companion diagnostic FG-3180, with an interim analysis expected in the second half of 2026.
Future Plans: The company is on track to submit the Phase 3 protocol for roxadustat in LR-MDS by Q4 2025 and is exploring further development options.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
